Review

asperulosidic acid content (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress asperulosidic acid content
Asperulosidic Acid Content, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n6246/Asperulosidic+Acid/10__1186_slash_s13765___024___00910___w-114-25-32
Average 93 stars, based on 2 article reviews

asperulosidic acid content - by Bioz Stars, 2026-10

93/100 stars

Images

Injection:

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis
Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Membrane:

Control:

Standard Deviation:

Cell Counting:

CCK-8 Assay:

Immunofluorescence:

Expressing:

Concentration Assay:

Western Blot:

In Vitro:

Reverse Transcription Polymerase Chain Reaction:

In Vivo:

Image Search Results

Intravitreal injection of ASPA treatment demonstrated a reduction in EIU. Rats were treated with ASPA 24 h before LPS inoculation through intraperitoneal, subconjunctival, and intravitreal routes at doses of 10, 30, and 100 μg/kg, and 125, 250, and 500 ng/eye, respectively. (A) A day prior to the LPS challenge, the LPS + PBS group exhibited pupil occlusion (black arrow), a fibrinous membrane (black arrow), and hypopyon (white arrow). No inhibitory impact on inflammation was observed in the groups receiving ASPA via intraperitoneal, subconjunctival, or 10 ng/eye intravitreal injection. At 24 h post-LPS injection, a slight fibrinous membrane formation and iris blood vessel dilation were noted in the 250 and 500 ng/eye intravitreal ASPA groups, indicating a dose-dependent treatment effect. Cular inflammation was absent in rats from both the control and the ASPA-injected intravitreal groups when LPS was not introduced. Magnification: 16×. (B) Clinical scores were conducted 24 h following the administration of LPS. Clinical scores of the eight distinct groups are depicted in a histogram, where the values are expressed as the mean ± standard deviation, with six eyes per group ( n = 6). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: Intravitreal injection of ASPA treatment demonstrated a reduction in EIU. Rats were treated with ASPA 24 h before LPS inoculation through intraperitoneal, subconjunctival, and intravitreal routes at doses of 10, 30, and 100 μg/kg, and 125, 250, and 500 ng/eye, respectively. (A) A day prior to the LPS challenge, the LPS + PBS group exhibited pupil occlusion (black arrow), a fibrinous membrane (black arrow), and hypopyon (white arrow). No inhibitory impact on inflammation was observed in the groups receiving ASPA via intraperitoneal, subconjunctival, or 10 ng/eye intravitreal injection. At 24 h post-LPS injection, a slight fibrinous membrane formation and iris blood vessel dilation were noted in the 250 and 500 ng/eye intravitreal ASPA groups, indicating a dose-dependent treatment effect. Cular inflammation was absent in rats from both the control and the ASPA-injected intravitreal groups when LPS was not introduced. Magnification: 16×. (B) Clinical scores were conducted 24 h following the administration of LPS. Clinical scores of the eight distinct groups are depicted in a histogram, where the values are expressed as the mean ± standard deviation, with six eyes per group ( n = 6). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: Injection, Membrane, Control, Standard Deviation

ASPA administration effectively reduces inflammation in EIU. Rats received intravitreal injections of ASPA at doses of 125, 250, and 500 ng/eye 24 h prior to LPS injection. Tissue samples were obtained 24 h after LPS treatment. At the 24-h mark post-LPS injection, a significant infiltration of inflammatory cells, indicated by black arrows, was detected in the anterior chamber, iris stroma, ciliary body, and vitreous body of the LPS + PBS group. (A) The intravitreal administration of ASPA at a dosage of 125 ng/eye failed to demonstrate any suppression of inflammation. (B) In the AqH, a considerable cell count was detected 24 h following LPS injection in both the LPS + PBS group and the group that received 125 ng/eye intravitreal injections. A notable reduction in AqH cell density was noted in the groups treated with 250 and 500 ng/eye of intravitreal ASPA, which was found to be dose-dependent. The scale bar is 50 μm. (C) The protein concentrations in the front chamber were measured across six separate trials. (D) The number of inflammatory cells in vitreous body. All the data are shown as means ± standard deviation ( n = 6, eye). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA administration effectively reduces inflammation in EIU. Rats received intravitreal injections of ASPA at doses of 125, 250, and 500 ng/eye 24 h prior to LPS injection. Tissue samples were obtained 24 h after LPS treatment. At the 24-h mark post-LPS injection, a significant infiltration of inflammatory cells, indicated by black arrows, was detected in the anterior chamber, iris stroma, ciliary body, and vitreous body of the LPS + PBS group. (A) The intravitreal administration of ASPA at a dosage of 125 ng/eye failed to demonstrate any suppression of inflammation. (B) In the AqH, a considerable cell count was detected 24 h following LPS injection in both the LPS + PBS group and the group that received 125 ng/eye intravitreal injections. A notable reduction in AqH cell density was noted in the groups treated with 250 and 500 ng/eye of intravitreal ASPA, which was found to be dose-dependent. The scale bar is 50 μm. (C) The protein concentrations in the front chamber were measured across six separate trials. (D) The number of inflammatory cells in vitreous body. All the data are shown as means ± standard deviation ( n = 6, eye). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: Injection, Cell Counting, Standard Deviation

ASPA improved cell connectivity reduction caused by LPS. CCK-8 assay of cell viability of RPE (A) and HRVEC (B) . (C) In HRVEC cells, the immunofluorescence assay demonstrated a marked decrease in the expression levels of ZO-1 and VE-cadherin following LPS treatment. The scale bar is 100 μm. ASPA at the concentration of 200 μg/mL could reverse the decrease in the expression induced by LPS (D,E) . The expression levels of ZO-1 and VE-cadherin were assessed using the western blot technique (F) . ASPA effectively counteracted the LPS-induced reduction in the expression of ZO-1 (G) and VE-cadherin (H) . All the data are shown as means ± standard deviation ( n = 3). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA improved cell connectivity reduction caused by LPS. CCK-8 assay of cell viability of RPE (A) and HRVEC (B) . (C) In HRVEC cells, the immunofluorescence assay demonstrated a marked decrease in the expression levels of ZO-1 and VE-cadherin following LPS treatment. The scale bar is 100 μm. ASPA at the concentration of 200 μg/mL could reverse the decrease in the expression induced by LPS (D,E) . The expression levels of ZO-1 and VE-cadherin were assessed using the western blot technique (F) . ASPA effectively counteracted the LPS-induced reduction in the expression of ZO-1 (G) and VE-cadherin (H) . All the data are shown as means ± standard deviation ( n = 3). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: CCK-8 Assay, Immunofluorescence, Expressing, Concentration Assay, Western Blot, Standard Deviation

ASPA decreased the release of proinflammatory mediators in vitro . RPE cells were pretreated with 200 μg/mL ASPA for 1 h before 50 ng/mL LPS stimulated RPE cells for 24 h. (A–D) RT-PCR served as the method for assessing the transcriptional levels of proinflammatory proteins ICAM-1, IL-6, MCP-1, and TNF-α. (E–I) Western blot was employed to assess the presence of ICAM-1, IL-6, MCP-1, and TNF-α in the samples. All the data are shown as means ± standard deviation ( n = 3). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA decreased the release of proinflammatory mediators in vitro . RPE cells were pretreated with 200 μg/mL ASPA for 1 h before 50 ng/mL LPS stimulated RPE cells for 24 h. (A–D) RT-PCR served as the method for assessing the transcriptional levels of proinflammatory proteins ICAM-1, IL-6, MCP-1, and TNF-α. (E–I) Western blot was employed to assess the presence of ICAM-1, IL-6, MCP-1, and TNF-α in the samples. All the data are shown as means ± standard deviation ( n = 3). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: In Vitro, Reverse Transcription Polymerase Chain Reaction, Western Blot, Standard Deviation

ASPA reduced the production of proinflammatory mediators in vivo . Before the injection of LPS, ASPA (500 ng/eye) was administered into the vitreous cavity of rats 24 h prior. Tissues were collected 24 h post-LPS administration. (A–D) Our analysis of ICAM-1, IL-6, MCP-1, and TNF-α expression levels was conducted using the RT-PCR. (E–I) Western blot was the chosen method for assessing the levels of the inflammatory markers ICAM-1, IL-6, MCP-1, and TNF-α. The data are presented as mean ± standard deviation ( n = 6, eye). * p < 0.05 significant difference.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA reduced the production of proinflammatory mediators in vivo . Before the injection of LPS, ASPA (500 ng/eye) was administered into the vitreous cavity of rats 24 h prior. Tissues were collected 24 h post-LPS administration. (A–D) Our analysis of ICAM-1, IL-6, MCP-1, and TNF-α expression levels was conducted using the RT-PCR. (E–I) Western blot was the chosen method for assessing the levels of the inflammatory markers ICAM-1, IL-6, MCP-1, and TNF-α. The data are presented as mean ± standard deviation ( n = 6, eye). * p < 0.05 significant difference.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: In Vivo, Injection, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Standard Deviation

ASPA inhibits RPE cells inflammation through the PI3K/Akt/NF-κB pathway. RPE cells were pretreated with 200 μg/mL ASPA for 1 h before 50 ng/mL LPS stimulated RPE cells for 24 h. Western blotting (A,E) was utilized to examine the levels of signaling proteins, including PI3K-p85, p-PI3K-p85 (F) , Akt, p-T308-Akt (G) , NF-κB, p-NF-κBp65 (B) , IKK, p-IKK (C) , IκB-α, and p-IκB-α (D) . The data are presented as mean ± standard deviation ( n = 3). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA inhibits RPE cells inflammation through the PI3K/Akt/NF-κB pathway. RPE cells were pretreated with 200 μg/mL ASPA for 1 h before 50 ng/mL LPS stimulated RPE cells for 24 h. Western blotting (A,E) was utilized to examine the levels of signaling proteins, including PI3K-p85, p-PI3K-p85 (F) , Akt, p-T308-Akt (G) , NF-κB, p-NF-κBp65 (B) , IKK, p-IKK (C) , IκB-α, and p-IκB-α (D) . The data are presented as mean ± standard deviation ( n = 3). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: Western Blot, Standard Deviation

ASPA was found to have a suppressive effect on EIU by modulating the PI3K/Akt/NF-κB signaling pathway. In rat model, ASPA was administered into the vitreous cavity at a dosage of 500 ng/eye, 24 h prior to LPS injection. Western blot analysis (A,E) was employed to determine the expression levels of key signaling proteins, including PI3K-p85, p-PI3K-p85 (F) , Akt, p-T308-Akt (G) , NF-κB, p-NF-κBp65 (B) , IKK, p-IKK (C) , IκB-α, and p-IκB-α (D) , in tissue samples obtained 24 h after LPS administration. The data are presented as mean ± standard deviation ( n = 6, eye). * p < 0.05 significantly different.

Journal: Frontiers in Medicine

Article Title: Asperulosidic acid inhibits the PI3K/Akt/NF-κB pathway to suppress endotoxin-induced uveitis

doi: 10.3389/fmed.2024.1524779

Figure Lengend Snippet: ASPA was found to have a suppressive effect on EIU by modulating the PI3K/Akt/NF-κB signaling pathway. In rat model, ASPA was administered into the vitreous cavity at a dosage of 500 ng/eye, 24 h prior to LPS injection. Western blot analysis (A,E) was employed to determine the expression levels of key signaling proteins, including PI3K-p85, p-PI3K-p85 (F) , Akt, p-T308-Akt (G) , NF-κB, p-NF-κBp65 (B) , IKK, p-IKK (C) , IκB-α, and p-IκB-α (D) , in tissue samples obtained 24 h after LPS administration. The data are presented as mean ± standard deviation ( n = 6, eye). * p < 0.05 significantly different.

Article Snippet: Additionally, ASPA (HY-N6246, MedChemExpress) and LPS (Sigma-Aldrich, St. Louis, MO, United States) were procured from the specified sources.

Techniques: Injection, Western Blot, Expressing, Standard Deviation

Review

asperulosidic acid content (MedChemExpress)

Structured Review

Images

Related Articles

Injection:

Membrane:

Control:

Standard Deviation:

Cell Counting:

CCK-8 Assay:

Immunofluorescence:

Expressing:

Concentration Assay:

Western Blot:

In Vitro:

Reverse Transcription Polymerase Chain Reaction:

In Vivo:

Similar Products

Image Search Results